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Title 
Metabolic phenotype of stage IV lung adenocarcinoma: relationship with epidermal 
growth factor receptor mutation  
Abstract 
Purpose Epidermal growth factor receptor (EGFR) mutation status is important in 
treatment stratification of stage IV lung adenocarcinoma. We evaluated the relationship 
between the maximum standardized uptake value (SUVmax) measured on PET/CT and 
EGFR mutations; and the value of SUVmax in predicting EGFR mutations. 
Patients and methods: Seventy-one stage IV lung adenocarcinoma patients with verified 
EGFR mutations (48 EGFR-mutant, 23 EGFR-wild type) having pre-treatment PET/CT 
were retrospectively reviewed. SUVmax of the primary tumors (n=71), nodal (n=246) 
and distant metastases (n=618) were compared between EGFR-mutant and EGFR-wild 
type adenocarcinoma by Mann-Whitney U-test. The receiver operating characteristics 
(ROC) curve and logistic regression were performed for factors, SUVmax, age, sex and 
smoking status. The significant predictors were assessed individually and in combination 
in discriminating EGFR mutation status. Statistical significance was assumed at p<0.05 
Results: The metastases in EGFR-mutant adenocarcinoma had lower SUVmax than 
EGFR-wild type adenocarcinoma (nodal SUVmax 3.4 vs. 5.5, distant metastasis 
SUVmax 3.4 vs. 4.7 respectively; both p<0.001). No statistical significant difference was 
observed in the primary tumors SUVmax between the two groups (SUVmax 7.4 vs. 8.1, 
p=0.311). A ROC-derived SUVmax ≦7.2 in metastasis could separate EGFR-mutant 
from EGFR-wild type adenocarcinoma (area under the curves, AUC, 0.71-0.74, p<0.05). 
SUVmax was a significant independent predictor and when combined with age, sex and 
smoking status, were highly predictive of EGFR mutation status (AUC 0.90) 
Conclusion: Low SUVmax in the metastasis favors the presence of EGFR mutations in 
stage IV lung adenocarcinoma and SUVmax is an independent predictor of EGFR 
mutations. 
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Introduction 
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of stage IV non-
small cell lung cancer (NSCLC), especially in adenocarcinoma. The drug efficacy is 
dependent on the presence of epidermal growth factor receptor (EGFR) mutations that 
confer favorable response to TKIs. Though demographic characteristics such as age, sex 
and smoking status were correlated factors with the presence of EGFR mutations, they 
were insufficiently sensitive to select individual for TKI therapy. Hence, the current 
recommendation remains in prioritizing EGFR mutation testing over other molecular 
predictive tests in all advanced stage lung adenocarcinoma 1. Obtaining sufficient tumor 
material of good quality to allow for EGFR mutations testing remains challenging in 
advanced disease when the primary tumor is not resectable 2. 
18-fluoro-deoxyglucose (18F-FDG) positron-emission tomography/computed tomography 
(PET/CT) forms an essential staging tool for NSCLC. The glucose metabolism has been 
found to be associated with disease aggressiveness and cell proliferation 3. Given that 
EGFR signaling transduction pathway is responsible for cell survival and proliferation 4, 
previous studies have explored the relationship between the metabolic uptake and EGFR 
mutations. These studies showed correlations of opposite trends between pre-treatment 
maximum standardized uptake value (SUVmax) of the primary tumor and the presence of 
EGFR mutations and one reported no correlation 5-9. There was significant design 
heterogeneity among these studies, which included patients with different stages of 
disease and of various histological subtypes, thus difficult to draw conclusive results 
from these studies.   
Herein, we aim to evaluate the metabolic signatures of the primary tumors and metastases 
in a Chinese cohort of stage IV lung adenocarcinoma in association to their EGFR 
mutation status and the value of SUVmax in predicting EGFR mutations.  
 
 
 
Materials and methods 
Patients 
EGFR mutations testing started at our hospital in 2009. We retrospectively identified all 
newly diagnosed therapy-naive patients with NSCLC who underwent staging PET/CT 
from January 2009 to January 2014. Inclusion criteria were (a) patients with histological 
confirmation of adenocarcinoma, (b) stage IV (both M1a and M1b) disease demonstrated 
either by PET/CT or proven by histology and (c) EGFR mutation status determined. 
Staging was based on the new 7th revised edition for lung cancer staging by the 
International Staging Committee of the International Association of the Study of Lung 
Cancer (IASLC) 10.  The study was approved by the institutional review board and the 
need for written informed consent was waived.  
Eighty-nine stage IV NSCLC patients were identified but EGFR mutation status was not 
verified in 17 of them due to insufficient tissue material.  One PET/CT was excluded due 
to technical error that prevented retrospective quantitative analysis. Thus, the study 
population comprised of 71 patients. The patients’ demographics characteristics; age, sex 
and smoking history were collected. Non-smokers were defined as those who never 
smoked or smoked less than 100 cigarettes in their lifetime, while patients who gave up 
smoking more than one year at the time of diagnosis were considered ex-smokers. The 
rest were categorized as current smokers5. 
EGFR mutation status 
EGFR mutations were tested on genomic DNA from frozen tumor tissues using Sanger 
sequencing of exons 18 to 21, or DNA extracted from formalin-fixed, paraffin-embedded 
tumors using allele-specific PCR (amplification refractory mutation system) (EGFR RGQ 
PCR Kit, Qiagen) according to previously described protocols 11, 12. Tumors harboring 
EGFR mutations on these exons were labeled as EGFR-mutant and those without were 
labeled as EGFR-wild type.  
 
 
PET/CT acquisition and analysis 
PET/CT examinations were performed using dedicated PET/CT scanner (Discovery 
VCT, 64-multislice CT, GE Healthcare Bio-Sciences Corp., Piscataway, New Jersey, 
USA). Patients were required to fast 6 hours prior to the examination and serum glucose 
was maintained below 180mg/dl before 370MBq 18F-FDG injection. An hour following 
18F-FDG injection, either a low-dose CT (field of view, 50 cm; pixel size, 3.91 mm; 0.5 
s/CT rotation, pitch 0.984:1; 2.5 mm intervals; 120 kVp; 80–200 mA) or contrast 
enhanced CT (same parameters but with 200-400mA, 1.5ml/kg intravenous contrast at a 
rate of 2.0 ml/sec) was performed for anatomical correlation and attenuation correction, 
covering from skull base to the upper thighs. This was followed by PET emission scan, 
taking approximately 3-4 min per bed position and 5-6 bed positions per patient.  PET 
images were reconstructed using 14 subsets and two iterations based on an ordered-subset 
expectation maximization iterative algorithm.  
All the examinations were retrospectively reviewed on dedicated ADW4.3 workstation 
(GE Healthcare, Milwaukee, Wisconsin, USA). Reviewers were blinded to the EGFR 
mutations at the time of review. Volume of interest (VOI) was placed to encompass the 
entire primary tumor, lymph node or metastasis, but carefully excluding tissue outside of 
the measured lesion by WSQ and XY to derive the SUVmax. Radiologist EL (3 years 
experience in PET/CT with special interest in thoracic imaging) subsequently verified all 
lesions and VOI contoured. Metastatic lymph nodes were defined as lymph nodes with 
increased metabolic activity compared to background mediastinal blood pool based on 
visual qualitative analysis. Only lesions with the longest axis equal or more than 1.0 cm 
were included in the analysis to avoid partial volume effect. The SUVmax was corrected 
based on lean body mass. In the presence of multiple metastatic lesions, one lymph node 
and one distant metastasis with the highest SUVmax in each patient were selected for 
subgroup analyses. The lesions that were not biopsied were verified by follow-up 
imaging by either PET/CT or CT based on EORTC and RECIST 1.1 criteria 
respectively13, 14. Tumors that responded in concordant fashion as the overall disease in 
the form of complete response, partial response, stable disease or disease progression 
were considered true positive tumors; whereas tumors that responded different from the 
overall disease were considered false positive tumors and would be excluded from 
analysis.  
Statistics 
Descriptive statistics were used for demographic data. Median value was expressed with 
ranges. Non-parametric Mann-Whitney U test was used to compare the difference in 
SUVmax between EGFR-mutant and EGFR-wild type adenocarcinoma. Receiver 
operating characteristics (ROC) curve was constructed to derive the optimal cut-off value 
for SUVmax in predicting EGFR mutation status. Demographic features (age, sex, 
smoking status) and SUVmax with p-value <0.05 in the univariate analysis were further 
analyzed by multivariate logistic regression to identify significant predictors for EGFR 
mutations.  The SUVmax was dichotomized by the ROC-derived cut-off value and age 
was treated as continuous variable for both univariate and multivariate analyses. ROC 
curves were constructed for individual predictor and combined factors in predicting 
EGFR mutations. Null hypothesis was rejected when p-value <0.05 and statistical 
significance was assumed. All analyses were performed using SPSS (version 20.0, 
Chicago, IL, USA).  
 
Results 
Patients and disease characteristics 
The median age of the study population was 65 years old (range 35-85 years-old). The 
median age of patients with EGFR-mutant adenocarcinoma (median 70 years-old, range 
41-85 years-old) was higher than patients with EGFR-wild type adenocarcinoma (median 
57 years-old, range 35-79 years-old) (p<0.001). Further clinical characteristics were 
tabulated in Table 1. The follow-up PET/CT or CT was performed at a median of 9.2 
months (1.1-44.8 months). Five patients had shorter follow-up period of less than 3 
months due to rapid disease progression given that our study cohort was stage IV 
adenocarcinoma with poor prognosis. 
There were 48 patients with EGFR-mutant adenocarcinoma (with 4 patients having 
double EGFR mutations, Table 1) and 23 patients with EGFR-wild type adenocarcinoma 
(Figures 1A and 1B). Forty-eight patients (30 EGFR-mutant and 18 EGFR-wild type) had 
nodal metastases with 246 metastatic lymph nodes evaluated. There were 618 distant 
metastases evaluated in 68 patients (45 EGFR-mutant and 23 EGFR-wild type). Three 
patients had their brain metastases resected at the time of initial diagnosis of underlying 
NSCLC prior to staging PET/CT, therefore not evaluated.  
18F-FDG avidity of tumors  
There was no difference in the SUVmax between the EGFR-mutant and EGFR-wild type 
primary tumors (p=0.311) (Figure 2, Table 2).  
The SUVmax of the EGFR-mutant lymph nodes was lower than EGFR-wild type 
adenocarcinoma (p<0.001) (Table 2). In subgroup analysis based on the highest nodal 
SUVmax, the metabolic uptake remained significantly lower in the EGFR-mutant lymph 
nodes, SUVmax 3.5 (1.1-10.5) than EGFR-wild type lymph nodes, SUVmax 7.1 (2.4-
19.1) (p=0.005, Figure 3A).  
The EGFR-mutant distant metastases had lower 18F-FDG avidity (p<0.001) (Table 2). 
The SUVmax of the most avid distant metastasis was lower in EGFR-mutant 
adenocarcinoma, SUVmax 5.8 (2.6-16.6) than EGFR-wild type metastasis, 8.4 (3.0-18.1) 
(p=0.006, Figure 3B). 
ROC curve analysis based on the most 18F-FDG-avid metastases 
When attempting to optimize the sensitivity and maintaining a high specificity (>80%), 
SUVmax ≦7.2 in both nodal and distant metastases could predict EGFR-mutant status. 
In lymph node categorization, the accuracy (Acc) 73%, sensitivity (Sen) 50%, specificity 
(Spec) 87%, positive predictive value (PPV) 69%, negative predictive value (NPV) 74%, 
area under the curve (AUC) 0.74, p=0.005 were achieved; whereas in distant metastasis, 
the diagnostic characteristics were Acc 72%, Sen 57%, Spec 80%, PPV 59%, NPV 78%, 
AUC 0.71, p=0.006 (Figure 4). 
 
Prediction of EGFR mutation status 
The SUVmax was dichotomized at SUVmax 7.2. In the univariate analysis, all factors 
tested (age, sex, smoking status and SUVmax) were significantly correlated with EGFR 
mutation status (all p<0.001). Subsequent multivariate logistic regression analysis 
demonstrated all factors were significant predictors (all p<0.001). ROC curves analysis 
showed that each individual factor could predict EGFR mutation status with AUC 
ranging from 0.58-0.74. When combining all 4 factors, they were highly predictive of 
EGFR mutations (AUC 0.90, Sen 82%, Spec 79%, PPV 85%, NPV 76%) (Figure 5) 15, 16. 
 
Discussion 
In this study, we demonstrated that the metastases, but not the primary tumor, from stage 
IV EGFR-mutant adenocarcinoma had significantly lower SUVmax than EGFR-wild 
type adenocarcinoma and that SUVmax was a significant independent predictor for 
EGFR mutations. When SUVmax was combined with easily accessible demographic 
parameters, namely age, sex and smoking status, these were highly predictive of EGFR 
mutations with an AUC 0.90 15, 16.  
The EGFR mutation status is important in selecting NSCLC for TKI therapy. The clinical 
challenge remains with obtaining adequate tumor tissue of good quality, often from small 
samples acquired from bronchoscopic fine needle aspiration or core needle biopsies, for 
EGFR mutation analysis. Even with sensitive PCR approaches, insufficient DNA 
extraction from these small samples can result in artifacts that preclude confident 
interpretation 17, as shown in 19% of our patients whom could not have their EGFR status 
verified and had to be excluded from the study cohort. This is often the limiting step in 
initiation of personalized treatment with TKIs.  
The low SUVmax in EGFR-mutant adenocarcinoma in our study may seem 
counterintuitive, given the role of EGFR in modulating cell survival. We propose that the 
cellular metabolism of the metastasis may have been altered following a series of 
complex cell-biological events, forming the invasion-metastasis cascade 18. It is plausible 
that the metabolic phenotype of EGFR-mutant primary tumor may differ from that of 
metastases. This biological adaptation supports our results in that the nodal and distant 
metastases from EGFR-mutant adenocarcinoma had lower SUVmax but not the primary 
tumor. The lower metabolic uptake in EGFR-mutant adenocarcinoma could be related to 
the lower proportion of GLUT-1 overexpression in mutant-EGFR adenocarcinoma, 23% 
compared to 58% in EGFR-wild type adenocarcinoma 19.  
Our study cohort was made up of all stage IV lung adenocarcinoma when compared to 
others published studies that included various stages and different histological subtypes 
of NSCLC (Table 3) 5-9. The inclusion of different histological subtypes is likely going to 
impact upon the semi-quantification of SUVmax, as squamous cell carcinoma is known 
to be more FDG avid than adenocarcinoma 20. Some studies concentrated in analyzing the 
primary tumors but not the metastases, therefore potentially masking the different 
metabolic phenotypes expressed by the EGFR-mutant and EGFR-wild type metastases 6, 
9. Huang et al. drew different conclusion from ours and suggested that SUVmax > 9.5 
was more likely to harbor EGFR mutations in 77 patients 5. The discrepancy maybe 
related to the evaluation protocol that only included SUVmax from the primary tumors 
and mediastinal nodal metastases but not distant metastases. Furthermore, the number of 
metastases per patient may have also affected the results. Higher SUVmax in NSCLC 
with EGFR-overexpression was observed in stage I resected primary tumors but the 
results could be again confounded by high proportion (24.3%) of squamous cell origin in 
the cohort 9.   
Despite statistical significant difference in the SUVmax between the two groups, 
substantial overlap was observed in the lower ranges of SUVmax of the metastases 
(Figure 3A and 3B) and tissue molecular confirmation should be performed whenever 
possible. In our study, identifying the EGFR mutation status was not feasible in 19% of 
the identified cases, indicating the clinical challenge in determining EGFR based on 
tissue molecular testing. Thus, SUVmax maybe a useful adjunct to demographic features 
in predicting EGFR mutations.    
This was a retrospective study that may introduce selection bias, likely explaining a high 
proportion of EGFR-mutant adenocarcinoma (68%) in our cohort. Our findings may be 
less applicable to populations that have lower incidence of EGFR mutation. The study 
only evaluated stage IV lung adenocarcinoma and would require further validation of our 
results in less advanced stage NSCLC. As clinically impractical and unethical, not all 
lesions were biopsied and analyzed individually for EGFR mutation status; this may 
introduce bias in the molecular analysis given disease heterogeneity and validation 
through follow-up imaging could be imprecise. Thus, we could have included 
inflammatory and reactive lymph nodes.  
 
Conclusion 
In conclusion, the metastases of EGFR-mutant stage IV adenocarcinoma have lower 
metabolic phenotype compared to EGFR-wild type metastases and SUVmax is a 
significant independent predictor of EGFR mutations.  
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Legends 
Figure 1 Maximum intensity projection of PET data in stage IV lung adenocarcinoma. A, 
EGFR-wild type primary tumor in the collapsed right lower lobe (SUVmax 16.9) with 
pleural, osseous and peritoneal metastases (SUVmax 1.8-6.8). FDG uptake in the right 
parotid gland was related to concurrent sialadenitis. B, EGFR-mutant primary tumor in 
the consolidated right lower lobe (SUVmax 8.5) with nodal and widespread osseous 
metastases (SUVmax 1.7-5.2). 
Figure 2. Box-plot of SUVmax of primary tumors of EGFR-mutant and EGFR-wild type 
adenocarcinoma. There was no statistical significant difference in the SUVmax of the 
primary tumors between EGFR-mutant (N=48) and EGFR-wild type (N=23) 
adenocarcinoma (p=0.311). The boxes represent the 25th-75th percentiles of the SUVmax 
and the crossbars denote the minimum and maximum values that were not outliers. The 
circle represents the mild outlier. 
Figure 3. Box-plots of SUVmax of metastases of  EGFR-mutant and EGFR-wild type 
adenocarcinoma. A, The highest nodal SUVmax from each patient in EGFR-mutant 
(N=30) and EGFR-wild type adenocarcinoma (N=18) was selected, and the difference 
was statistically significant (p=0.005). B, The distant metastasis with highest SUVmax 
from each patient in EGFR-mutant (N=45) and EGFR-wild type adenocarcinoma (N=23) 
was selected, and the difference was statistically significant (p=0.006). The boxes 
represent the 25th-75th percentiles of the SUVmax and the crossbars denote the minimum 
and maximum values that were not outliers. The circle represents the mild outlier and the 
asterisk is the extreme outlier. SUVmax: maximum standardized uptake value; EGFR: 
epidermal growth factor receptor. 
Figure 4. ROC curves of nodal and metastasis SUVmax in predicting EGFR mutations. A 
SUVmax ≦7.2 would predict EGFR mutations with high specificity. A, In nodal 
metastasis, Acc 73%, AUC 0.74, p=0.005. B, In distant metastasis, Acc 72%, AUC 0.71, 
p=0.006. ROC: receiver operating characteristics; SUVmax: maximum standardized 
uptake value; EGFR: epidermal growth factor receptor; Acc: accuracy; AUC: area under 
the curve.  
Figure 5. ROC curves of individual predictors and combined predictive factors 
(SUVmax, age, sex and smoking status) in determining EGFR mutation status. ROC: 
receiver operating characteristics; AUC: area under the curve, followed by 95% 
confidence intervals in brackets. 
Table 1. The clinical characteristics of the study population in respect to EGFR mutation 
status and the frequencies of EGFR mutation types. EGFR: epidermal growth factor 
receptor; N: number of patients. 
Table 2. The metabolic parameters of the primary tumors and metastases in association 
with EGFR mutation status. EGFR: epidermal growth factor receptor; n: number of 
lesions; *: statistical significance. 
Table 3. Summary of the studies evaluated the relationship between metabolic uptake and 
EGFR mutation status. N: total number; n: number in subgroups; ADC: adenocarcinoma; 
EGFR: epidermal growth factor receptor; LN: lymph node; SUV: standardized uptake 
value; †only mutations in exons 19 and 21; ‡EGFR status determined by EGFR-
overexpression on immunohistochemistry. 
TABLE 1. The clinical characteristics of the study population in respect to EGFR 
mutation status and the frequencies of EGFR mutation types. EGFR: epidermal growth 
factor receptor; N: number of patients. 
 EGFR-mutant  
(N) 
EGFR-wild type  
(N) 
Total  
(N) 
 
 
Smoking 
status 
 
Non-smoker  39 12 51 
Smoker/ 
ex-smoker  
8 11 19 
Undetermined 1 0 1 
 
Sex 
 
Female  31 7 38 
Male  17 16 33 
 
EGFR 
mutations 
 
Exon 21 27   
52 Exon 20 5  
Exon 19 15  
Exon 18 5  
Negative  23 23 
 
TABLE 2. The metabolic parameters of the primary tumors and metastases in association 
with EGFR mutation status. EGFR: epidermal growth factor receptor; n: number of 
lesions; *: statistical significance. 
 EGFR-mutant EGFR-wild 
type 
p-value 
Primary tumor SUVmax 
Median (range) 
n=48 n=23  
7.4 
(2.5-15.2) 
8.1 
(1.3-22.5) 
0.311 
Nodal metastasis 
SUVmax 
Median (range) 
n=118 n=128  
3.4 
(1.1-10.5) 
5.5 
(1.3-19.1) 
<0.001* 
Distant metastasis 
SUVmax 
Median (range) 
n=389 n=229  
3.4 
(0.9-16.6) 
4.7 
(1.4-18.1) 
<0.001* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 3. Summary of the studies evaluated the relationship between metabolic uptake and EGFR mutation status. N: total number; 
n: number in subgroups; ADC: adenocarcinoma; EGFR: epidermal growth factor receptor; LN: lymph node; SUV: standardized 
uptake value; †only mutations in exons 19 and 21; ‡EGFR status determined by EGFR-overexpression on immunohistochemistry. 
Studies N Disease 
stage (n) 
Histology EGFR   
mutant: wild type (n) 
Lesions 
measured 
Metabolic 
parameters 
Findings 
Huang et 
al.5 
77 IIIB/IV 
(15/62) 
ADC 49:28 
 
Primary 
tumor, 
mediastinal 
LN 
SUVmax High SUVmax was predictive 
of EGFR mutations 
Na et al.6 100 I/II/III/IV 
(39/18/38/5) 
ADC,  
non-ADC 
21:79† Primary 
tumor 
SUVmax Low SUV was predictive of 
EGFR mutations 
Mak et al.7  100 I-IV 
(32/8/18/42) 
ADC,  
non-ADC 
24:76 
 
Primary 
tumor, one 
LN, one 
metastasis 
SUVmax Low SUV was associated 
with EGFR mutations 
Chung et 
al.8 
106 I-IV 
(12/7/27/60) 
ADC 42:64 
 
Primary 
tumor, one 
metastasis 
SUVmax Not predictive of EGFR 
mutations 
All MTV, 
TLG 
Lee et al.9 167 I 
(167) 
ADC,  
non-ADC 
42:125‡ 
 
Primary 
tumor 
SUVmax High SUVmax was 
associated with EGFR 
overexpression 
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